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Abstract. 
 
Duchenne muscular dystrophy is a fatal mus-
cle disease that is often associated with cognitive im-
pairment. Accordingly, dystrophin is found at the mus-
cle sarcolemma and at postsynaptic sites in neurons. In 
muscle, dystrophin forms part of a membrane-spanning 
complex, the dystrophin-associated protein complex 
(DPC). Whereas the composition of the DPC in muscle 
is well documented, the existence of a similar complex 
in brain remains largely unknown. To determine the 
composition of DPC-like complexes in brain, we have 
examined the molecular associations and distribution 
of the dystrobrevins, a widely expressed family of dys-
trophin-associated proteins, some of which are compo-
nents of the muscle DPC. 
 
b
 
-Dystrobrevin is found in 
neurons and is highly enriched in postsynaptic densities 
(PSDs). Furthermore, 
 
b
 
-dystrobrevin forms a speciﬁc 
complex with dystrophin and syntrophin. By contrast, 
 
a
 
-dystrobrevin-1 is found in perivascular astrocytes and 
Bergmann glia, and is not PSD-enriched. 
 
a
 
-Dystrobre-
vin-1 is associated with Dp71, utrophin, and syntrophin. 
In the brains of mice that lack dystrophin and Dp71, 
the dystrobrevin–syntrophin complexes are still 
formed, whereas in dystrophin-deﬁcient muscle, the as-
sembly of the DPC is disrupted. Thus, despite the simi-
larity in primary sequence, 
 
a
 
- and 
 
b
 
-dystrobrevin are 
differentially distributed in the brain where they form 
separate DPC-like complexes. 
Key words: dystrobrevin • dystrophin • synapse • 
postsynaptic density • astrocyte
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UCHENNE
 
 muscular dystrophy (DMD)
 
1
 
 is the most
common inherited muscle disease and one of the
most severe. Although the primary cause of mor-
tality in DMD patients is respiratory and cardiac failure
brought on by muscle degeneration, other organ systems
are implicated in the disease. Almost one third of DMD
patients have mild mental retardation (Lidov, 1996). Dys-
trophin, the protein product of the DMD gene, is located
at the postsynaptic membrane of cortical and Purkinje
neurons, and is a component of the postsynaptic density
(PSD; Lidov et al., 1990; Kim et al., 1992). These findings
suggest that dystrophin plays an important role in the
brain, where it may be involved in synapse function or in
synaptic architecture.
In muscle, where the majority of studies have been con-
ducted, dystrophin is associated with a protein complex,
the dystrophin-associated protein complex (DPC), located
at the sarcolemma (Yoshida and Ozawa, 1990; Ervasti and
Campbell, 1991). In dystrophin-deficient muscle, this com-
plex is disrupted, causing a severe reduction in the levels
of the DPC at the membrane (Ervasti et al., 1990). The
DPC can be subdivided into three distinct components,
the dystroglycan complex, the sarcoglycan complex, and
the cytoplasmic complex (reviewed by Blake and Davies,
1997).
The cytoplasmic complex is composed of 
 
a
 
-dystrobrevin
and the syntrophins (
 
a
 
, 
 
b
 
1, and 
 
b
 
2). In contrast to the
sarcoglycans, which are only expressed in cardiac and skel-
etal muscle, components of the cytoplasmic complex and
dystroglycan are found in many tissues, including the
brain. 
 
a
 
-Dystrobrevin is a dystrophin-related protein that
binds directly to the COOH terminus of dystrophin and to
the syntrophins (Blake et al., 1996; Nawrotzki et al., 1998;
Peters et al., 1998). Although clearly important for muscle
function, 
 
a
 
-dystrobrevin is also thought to be involved
in synaptic transmission at the neuromuscular junction
(NMJ) and in intracellular signaling (Sanes et al., 1998;
Grady et al., 1999). Similarly, members of the syntrophin
family of proteins can bind to other signaling proteins,
such as neuronal nitric oxide synthase (nNOS), voltage-
gated sodium channels, stress-activated kinase 3, and mi-
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crotubule-associated serine/threonine kinase (Brenman
et al., 1995; Gee et al., 1998; Hasegawa et al., 1999; Lu-
meng et al., 1999). These interactions suggest that the cy-
toplasmic components of the DPC may be directly in-
volved in anchoring signaling proteins or ion channels to
the sarcolemma in proximity to dystrophin.
Recently, a second member of the dystrobrevin family,
 
b
 
-dystrobrevin, was identified (Peters et al., 1997; Blake
et al., 1998; Puca et al., 1998). The 
 
b
 
-dystrobrevin gene en-
codes several alternatively spliced isoforms that are ex-
pressed predominantly in the brain and kidney, but not in
muscle (Peters et al., 1997; Blake et al., 1998). In common
with 
 
a
 
-dystrobrevin, 
 
b
 
-dystrobrevin also binds to dystro-
phin and syntrophin (Peters et al., 1997; Blake et al., 1998).
Interestingly, in polarized epithelial cells, 
 
b
 
-dystrobrevin,
the dystrophin-related protein utrophin, and 
 
b
 
2-syntro-
phin form a complex at the basolateral surface (Kachinsky
et al., 1999). These data suggest that 
 
b
 
-dystrobrevin, along
with other components of the DPC, is involved the organi-
zation of specialized submembranous domains.
By analogy to the situation in muscle, a neuronal dystro-
phin-like complex may contribute to the etiology or neu-
ropathology of cognitive impairment in DMD patients.
However, whereas dystrophin is only expressed in neu-
rons, several components of the DPC, such as dystrogly-
can and laminin-2, are associated with the glial/vascular in-
terface (Jucker et al., 1996; Tian et al., 1996). Furthermore,
utrophin and 
 
b
 
2-syntrophin, which are concentrated at the
NMJ in muscle, are both associated with the cerebral mi-
crovasculature (Khurana et al., 1992; Lumeng et al., 1999).
Thus, a dystrophin-like complex that is associated with mi-
crovascular glia exists in the brain. However, this complex
does not contain dystrophin and is therefore not equiva-
lent to the muscle described DPC.
To gain insight into the composition and location of
DPC-like complexes in the brain, we have determined the
distribution and molecular interactions of 
 
a
 
- and 
 
b
 
-dystro-
brevin with dystrophin and its isoforms. We have shown
that 
 
b
 
-dystrobrevin is a neuronal, PSD-enriched, dystro-
phin-binding protein. By contrast, 
 
a
 
-dystrobrevin-1 is
found in glia, where it is primarily associated with the dys-
trophin isoform Dp71. Furthermore, both proteins assem-
ble into distinct complexes with syntrophin in the brain
that are maintained in the absence of dystrophin or Dp71.
These data suggest that 
 
b
 
-dystrobrevin is part of a neu-
ronal DPC-like complex and may be involved in the
compound phenotype of cognitive dysfunction in DMD
patients. Our studies also highlight some fundamental dif-
ferences between the molecular pathology of dystrophin
deficiency in brain, compared with muscle.
 
Materials and Methods
 
Antibody Production
 
The following peptides were synthesized, coupled to keyhole limpet
hemocyanin, and injected into New Zealand white rabbits: 
 
b
 
521, NH
 
2
 
-
CTGSPHTSPTHGGGRPM; pan-db, NH
 
2
 
-CRVEHEQASQPTPEKA-
QQNP. Both antibodies were affinity-purified from the sodium sulphate
precipitated IgG fraction of rabbit sera on immobilized peptide col-
umns following the manufacturer’s recommendations (Sulfolink,
Pierce and Warriner). The antidystrophin antibody 2166 was raised
against the last 17 amino acids of murine dystrophin and detects all
 
dystrophin isoforms. The antidystrophin antibody 2401 was raised
against the alternatively spliced, hydrophobic COOH terminus of dys-
trophin, and detects Dp71. The antiutrophin polyclonal antibody,
URD40, was raised against the distal rod domain of mouse utrophin
and is preabsorbed against dystrophin. The SYN1351 antisyntrophin
mAb was kindly supplied by Prof. Stan Froehner (University of North
Carolina, Chapel Hill, NC; Froehner et al., 1987). The MANDRA1 an-
tidystrophin mAb was kindly supplied by Prof. Glenn Morris (North
East Wales Institute of Higher Education, Wrexham, UK; Nguyen et
al., 1992). The PSD-95 and Munc-18 mAbs were purchased from
Transduction Laboratories. The other dystrobrevin antisera, 
 
a
 
1CT-FP
and 
 
b
 
CT-FP, have been described previously (Blake et al., 1998;
Nawrotzki et al., 1998).
 
Immunocytochemistry
 
Adult rats and mice were given an overdose of sodium pentobarbital (60
mg/kg i.p.) and the tissue was fixed by transcardiac perfusion with either
4% paraformaldehyde in 0.1 M phosphate buffer (pH 7.4), Bouin’s fixa-
tive, or 70% ethanol in distilled water. The brains were removed, post-
fixed overnight at 4
 
8
 
C, dehydrated, and paraffin-embedded. Sections were
cut at 10–20 
 
m
 
m in the transverse or sagittal planes and mounted on gela-
tin-coated slides. Sections were stained with rabbit antibodies, 
 
b
 
521 (1:
200), 
 
a
 
1CT-FP (1:500), or 2166 (1:500), and mouse monoclonal antizebrin
II (1:200) at the dilutions shown (Brochu et al., 1990). Indirect peroxidase
immunocytochemistry was performed on the slide as described previously
(Eisenman and Hawkes, 1993), with either rabbit anti–mouse IgG or goat
anti–rabbit IgG conjugated to HRP as appropriate as the secondary anti-
body, and diaminobenzidine as the chromogen. Coverslips were applied
with Permount. Images of sections and whole-mounts were digitally cap-
tured using a Sensys Camera (Optikon Corp. Ltd.) running under V for
Windows. Montages were constructed using Adobe Photoshop 4.0. The
images were cropped and corrected for brightness and contrast, but not
otherwise manipulated.
For fluorescence microscopy, 10-
 
m
 
m fixed sections were cut onto Su-
perFrost Plus slides (BDH). The sections were air dried and blocked in
10% normal donkey serum in TBS (150 mM NaCl, 50 mM Tris, pH 7.5)
for 30 min. The sections were incubated with the primary antibody for 1 h,
washed twice for 5 min in TBS, and then incubated with a 1:400 dilution of
CY3-conjugated donkey anti–rabbit IgG (Jackson ImmunoResearch Lab-
oratories, Inc.) for another hour. Slides were washed twice for 5 min in
TBS and mounted in Vectashield (Vector Laboratories) fluorescence me-
dium containing 4
 
9
 
,6-diamidino-2-phenylindole (DAPI). Slides were
viewed with a Leica DMRE fluorescence microscope. For peptide block-
ing experiments, 
 
b
 
521 was preincubated with the immunizing peptide (25 
 
m
 
M
in TBS) or an unrelated peptide for 1 h at room temperature before appli-
cation to the section.
 
Subcellular Fractionation and
Synaptosome Preparation
 
Subcellular fractions, including synaptic membranes (SMs) and PSDs,
were prepared from rat forebrain homogenates as described previously
(Willmott et al., 1991; Mummery et al., 1996). 20 
 
m
 
g of protein from each
fraction was separated on an 8% SDS-polyacrylamide gel, transferred to
nitrocellulose membranes, and incubated with an appropriate antibody.
Crude synaptosomes were prepared from mouse brain following the
method described by Blackstone et al. (1992). The crude synaptosomes
were resuspended in PBS and stored at 
 
2
 
20
 
8
 
C. Proteins were solubilized
from synaptosome pellets by resuspending them in 1 M Tris HCl, pH 8.0,
100 mM NaHCO
 
3
 
, pH 11.5, or 2% detergent (SDS, sodium deoxycholate,
Tween-20, Triton X-100, 
 
N
 
-lauroylsarcosine, digitonin) in PBS. After in-
cubating the synaptosomes at 4
 
8
 
C for 30 min, the suspension was placed in
a bench-top centrifuge and spun at 50,000 
 
g
 
av
 
 for 30 min at 4
 
8
 
C. Soluble
proteins extracted in the supernatant were removed and the resulting pel-
let was resuspended in the original volume of PBS. After the addition of
an equal volume of 2
 
3
 
 sample buffer (125 mM Tris-HCl, pH 6.8, 4% SDS,
20% [vol/vol] glycerol, 5% [vol/vol] 2-mercaptoethanol) to each sample,
the protein extracts were denatured and resolved by SDS-PAGE. The dis-
tribution of specific proteins contained in each fraction was determined by
Western blotting with an appropriate antibody.
 
Immunoprecipitation
 
Tissue extracts from mouse and rat brain, and rat liver were prepared by 
Blake et al. 
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homogenizing 
 
z
 
2 g of freshly dissected tissue in 10 ml of 50 mM Tris, pH
7.4, 2.5 mM EDTA, plus protease inhibitors (Sigma Chemical Co.). The
homogenate was centrifuged at 141,000 
 
g
 
av
 
 for 45 min at 4
 
8
 
C and the re-
sulting pellet was rehomogenized in 10 ml of RIPA buffer (150 mM NaCl,
50 mM Tris, pH 8.0, 1% [vol/vol] Triton X-100, 1% [wt/vol] sodium de-
oxycholate, 0.1% [wt/vol] SDS, 2.5 mM EDTA, plus protease inhibitors).
After incubation on ice for 30 min, the homogenate was centrifuged at
141,000 
 
g
 
av
 
 for 45 min at 4
 
8
 
C. Approximately 1 mg of RIPA-soluble pro-
tein in 500 
 
m
 
l was incubated with 4 
 
m
 
g of affinity-purified polyclonal anti-
body for 6 h at 4
 
8
 
C on a blood mill. Immune complexes were captured by
the addition of 50 
 
m
 
l of goat anti–rabbit conjugated magnetic beads
(MagnaBind, Pierce and Warriner). After an overnight incubation at 4
 
8
 
C,
the beads were extensively washed in RIPA wash buffer (150 mM NaCl,
50 mM Tris, pH 8.0, 0.2% [vol/vol] Triton X-100, 0.2% [wt/vol] sodium
deoxycholate, 0.02% [wt/vol] SDS, plus protease inhibitors). Immunopre-
cipitated proteins were eluted by boiling in 100 
 
m
 
l of SDS/urea buffer (4 M
urea, 3.8% SDS, 20% [vol/vol] glycerol, 75 mM Tris, pH 6.8, 5% [vol/vol]
2-mercaptoethanol). The immunoprecipitated proteins were separated on
8 or 10% SDS polyacrylamide gels, transferred to nitrocellulose, and de-
tected with antibodies using standard methods.
 
Results
 
Characterization of 
 
b
 
-Dystrobrevin–specific Antisera
 
To establish the locations of 
 
a
 
- and 
 
b
 
-dystrobrevin in the
CNS, we produced antibodies that were isoform-specific.
Since the sequences of the dystrobrevins are very similar, a
 
peptide was chosen from the 
 
b
 
-dystrobrevin sequence that
had minimal homology to the 
 
a
 
-dystrobrevin sequence
(Fig. 1 A). The 
 
b
 
-dystrobrevin antiserum, 
 
b
 
521, was char-
acterized extensively for cross-reactivity with 
 
a
 
-dystrobre-
vin by immunoblotting and on sections (Fig. 1 B). On im-
munoblots of fusion proteins containing the COOH
termini of 
 
a
 
- or 
 
b
 
-dystrobrevin, 
 
b
 
521 only detected 
 
b
 
-dys-
trobrevin. By contrast, the pan-db antibody was raised
against a sequence that is common to both proteins and
detects both proteins on blots (Fig. 1 B). On sections of
mouse hippocampus region CA1, 
 
b
 
521 stained the den-
drites, soma, and nuclei of pyramidal neurons (Fig. 1 C).
All labeling was blocked by preincubation with the immu-
nizing peptide (Fig. 1 C), but not by preincubation of 
 
b
 
521
with an unrelated peptide (data not shown).
 
Immunolocalization of 
 
b
 
-Dystrobrevin in the Brain
 
To determine the cellular and subcellular localization of
 
b
 
-dystrobrevin in the brain, coronal sections of rat and
mouse brain were stained with antibody 
 
b
 
521. The distribu-
tion of immunoreactivity was essentially identical in rats and
mice, and did not depend on the method of fixation. Further-
more, preincubation of 
 
b
 
521 with the immunizing peptide
completely abolished immunolabeling (data not shown).
Figure 1. Characterization of
antidystrobrevin polyclonal
antibodies. A, Alignment of
the sequences of a- and b-dys-
trobrevin showing the peptide
sequences used for immuniza-
tion. B, Western blotted fu-
sion proteins, trx-m13c1 (b,
b-dystrobrevin COOH termi-
nus) and trx-m871 (a,  a-dys-
trobrevin COOH terminus)
were incubated with antibod-
ies, b521, and pan-DB. b-Dys-
trobrevin is only detected with
b521, whereas the pan-db anti-
body detects both fusion pro-
teins. The lower molecular
weight bands detected by each
antibody are specific pro-
teolytic fragments of the b-dys-
trobrevin fusion protein. The
positions of the molecular
weight standards are indicated.
C, Immunofluorescence local-
ization of b-dystrobrevin in
hippocampal pyramidal neu-
rons. b521 specifically labels
the dendrites (arrows), soma,
and nuclei of pyramidal neu-
rons in CA1 of the mouse hip-
pocampus. This labeling is
abolished by preincubation
with the immunizing peptide.
Sections have been double-
stained with DAPI to show the
position of the nuclei. Note
that only a subset of nuclei are
stained with b521. Bar, 50 mm. 
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b
 
-Dystrobrevin immunoreactivity was detected in neu-
rons. In the isocortex (Fig. 2 E), the reaction product is de-
posited most prominently in the somata (including the nu-
clei) and the dendrites of the pyramidal cells (Fig. 2 E).
Other cortical neurons are also stained. Similarly, in the
hippocampus (Fig. 2, A and B), immunoreactivity is most
prominent in CA1, CA2, and CA3 neurons, where the re-
action product is also found in the initial segments of den-
drites. Neuronal somata are stained in other hippocampal
regions as well. Somatal staining also characterizes the cer-
ebellum (Fig. 2 F), where the Purkinje cells, the molecular
layer interneurons, and the granule cells are immunoreac-
tive. In all cases, there is also weak axonal staining. Exam-
ples are shown for the brainstem, where strong immunore-
activity is detected in axon fascicles associated with the
spinal trigeminal tract (Fig. 2 E) and in the internal cap-
sule (Fig. 2 D).
 
Immunolocalization of 
 
a
 
-Dystrobrevin-1 in the Brain
 
The 
 
a
 
1CT-FP antibody was used to locate 
 
a
 
-dystrobrevin-1
in brain sections. As for 
 
b
 
-dystrobrevin, there were no sig-
nificant species differences, and the same distribution was
seen with all methods of fixation used. 
 
a
 
-Dystrobrevin-1 is
expressed by perivascular astrocytes in a pattern that is
reminiscent of utrophin immunoreactivity (Khurana et al.,
1992). Seen at low magnification, reaction product is de-
posited throughout the brain (Fig. 3 A). In the isocortex,
Figure 2. Immunolocaliza-
tion of b-dystrobrevin in rat
brain. The distribution of
b-dystrobrevin immunoreac-
tivity in transverse sections
through the adult rat brain
was determined with b521.
A, Hippocampus (low
power). The reaction prod-
uct is deposited in the CA1,
CA2, CA3, and the dentate
gyrus (DG). There is little
staining of the corpus callo-
sum (cc). Bar,  500  mm. B,
Hippocampus (midline to the
left). Reaction product is
found primarily in the neu-
ronal somata. Staining is
strongest in neurons of CA3,
where the initial dendrite
segments are also immunore-
active. The neurons of the
dentate gyrus (DG) are also
clearly labeled. Bar, 100 mm.
C, Reaction product is de-
posited in the interpolar
spinal trigeminal nucleus
(Sp5I), both in the nuclei of
large neurons and in axon
bundles cut longitudinally
(arrowheads) and trans-
versely (arrows) associated
with the spinal trigeminal
tract (spt). Bar, 100 mm. D,
Axonal immunoreactivity in
the internal capsule (ic) and
associated axon bundles in
the caudate-putamen (cp)
and thalamus (th). Bar,  100
mm. E, Isocortex. Layer I is
to the right. The nuclei of the
pyramidal cells are promi-
nently immunoreactive. In
addition, reaction product is
deposited in the pyramidal
cell dendrites (dendritic fasi-
cles are indicated by arrow-
heads). Bar, 200 mm. F, Cerebellum. The somata and nuclei of all neuronal types are immunoreactive: the stellate and basket cells in the
molecular layer (ml), the Purkinje cells in the Purkinje cell layer (PCL), and the granule cells in the granular layer (gl). In addition, the
axons in the white matter (wm) are weakly stained. Bar, 100 mm.Blake et al. Dystrophin-like Complexes in Brain 649
the only prominent staining is associated with the vascula-
ture (Fig. 3 B). In the hippocampus, in addition to staining
of blood vessels, there is prominent astroglial immunore-
activity (Fig. 3 C). There are also conspicuous regional dif-
ferences in staining intensity. Most reaction product is de-
posited in the dentate gyrus and CA2/CA3, with much less
immunoreactivity in CA1. A similar combination of peri-
vascular and astroglial immunoreactivity is seen in the cer-
ebellum (Fig. 3, D–G). At low magnification, a-dystrobre-
vin-1 immunoreactivity is clearly laminar, with moderate
staining of the molecular layer, speckled staining in the
granular layer, and little, if any, immunoreactivity in the
white matter tracts (Fig. 3 D). No regional differences are
apparent in the cerebellum. The granular layer immunore-
Figure 3. Immunolocaliza-
tion of a-dystrobrevin-1 in
rat and mouse brain. The dis-
tribution of a-dystrobrevin-1
immunoreactivity in trans-
verse sections through the
adult rat (A–F) and mouse
brain (G) was determined
with  a1CT-FP. A, Low-
power view through the fore-
brain. Reaction product is
deposited in the cortex (cx)
and hippocampus (hi), but
little immunoreactivity is de-
tected in the corpus callosum
(cc). Bar, 1 mm. B, In the iso-
cortex, the reaction product
is deposited primarily in
blood vessels. Bar,  200  mm.
C, Hippocampus (midline to
the left). Reaction product is
found primarily in glial cells.
There are prominent re-
gional differences in staining
intensity. Most reaction
product is deposited in the
dentate gyrus (dg) and CA2/
CA3. There is much less im-
munoreactivity in CA1. Bar,
100 mm. D, Cerebellum. At
low magnification, immu-
noreactivity is clearly lami-
nar, with moderate staining
of the molecular layer (ml),
speckled staining in the gran-
ular layer (gl), and little, if
any, immunoreactivity in the
white matter tracts. Bar, 500
mm. E, Cerebellar reaction
product in the granular layer
is confined to the blood ves-
sels. Vascular staining is also
present in the molecular
layer. There is no neuronal
staining, e.g., granule cells
in the granular layer or
Purkinje cells in the Purkinje
cell layer (PCL). Bar,  200
mm. F, Cerebellar immu-
noreactivity in the molecular
layer is concentrated in the
small somata of the Berg-
mann glia, scattered among
the unstained Purkinje cell
somata in the Purkinje cell
layer, and is also expressed diffusely throughout the molecular layer in the Bergmann radial glial processes. Bar, 100 mm. G, Cerebellar
immunoreactivity in the molecular layer of the adult mouse. The distribution of immunoreactivity is similar to that in the rat, except
that the radial nature of the Bergmann glial fibers in the molecular layer is more easily recognized. Bar, 100 mm.The Journal of Cell Biology, Volume 147, 1999 650
activity is confined to the vasculature, and there is no stain-
ing of granule cells (Fig. 3 E). At higher magnification, the
reaction product in the molecular layer is concentrated in
the Bergmann astroglial cells, where both the somata (Fig.
3 F) and the radial glial processes (Fig. 3, F and G) are
stained. The Purkinje cells were not immunoreactive.
Immunolocalization of Dystrophin and Its Isoforms in 
the Brain
The two major dystrophin isoforms present in brain are
dystrophin and Dp71. In addition to these products,
Dp140 is also found as a minor component in brain ex-
tracts. To investigate the location of dystrophin-immu-
noreactive proteins in the brain, sections of rat and mouse
brain were stained with the antibody 2166 that detects all
dystrophin isoforms. This antibody gave a complex stain-
ing pattern attributable to the presence of three different
proteins (Fig. 4). In the isocortex, 2166 labeled neuronal
somata and blood vessels (Fig. 4 A). In the cerebellar cor-
tex, Purkinje cell somata are labeled, along with dendrites
in the molecular layer (Fig. 4 B). There is weak labeling of
granule cells and little, if any, labeling in the white matter
(Fig. 4 B). A novel feature of the dystrophin isoform ex-
pression pattern is that the levels of staining intensity vary
in a consistent fashion between Purkinje cells. At low mag-
nification, the labeling of Purkinje cell dendrites is nonuni-
form and appears as a symmetrical and reproducible
parasagittal banded appearance when viewed in the trans-
verse plane (Fig. 4 C). This distribution is reminiscent of
the pattern revealed by immunostaining for the well-
known Purkinje cell band marker zebrin II. When the pat-
tern of dystrophin isoform expression is compared with
that of zebrin II (Fig. 4 D; Brochu et al., 1990; Eisenman
and Hawkes, 1993; Ahn et al., 1994). It is evident that the
Purkinje cells which preferentially express dystrophin are
zebrin II negative. This pattern of dystrophin immunore-
activity in cerebellar striations is similar to the high micro-
tubule-associated protein (MAP) 1A expressing subset
(Touri et al., 1996).
Distribution of the Dystrobrevins in Subcellular and 
Synaptic Fractionations
The differential location of b- and a-dystrobrevin-1 in
neurons and glia, respectively, suggests that the dystrobre-
vins could be independent, cell type-restricted ligands for
dystrophin and its isoforms in the brain. To test this hy-
pothesis, we examined the subcellular distribution of the
dystrobrevins and the molecular organization of dystro-
brevin-containing protein complexes. The subcellular dis-
tribution of the dystrobrevins was determined by immuno-
Figure 4. Immunolocaliza-
tion of dystrophin and its iso-
forms in rat brain. The dis-
tribution of dystrophin
immunoreactivity in trans-
verse sections was deter-
mined with the 2166 anti-
body. A, In the isocortex,
neuronal somata and blood
vessels are labeled. B, In the
cerebellar cortex, Purkinje
cell somata are labeled in the
Purkinje cell layer (PCL),
and their dendrites are seen
in the molecular layer (ml).
There is weaker granule cell
immunoreactivity in the gran-
ular layer (gl) and little or
no immunoreactivity in the
white matter (wm). Bar (A
and B), 100 mm. C, Cerebel-
lar cortex. At low magnifica-
tion, the labeling of Purkinje
cell dendrites is clearly non-
uniform and reveals alternat-
ing parasagittal bands of
Purkinje cell dendrites (seen
here flanking the midline in
lobule VIII). D, Serial sec-
tion labeled with the Purkinje
cell band marker, antizebrin
II. The P11 band at the mid-
line and the P21 bands later-
ally are labeled. The antize-
brin II-negative Purkinje cell
bands preferentially express
dystrophin. Bar (C and D),
200  mm.Blake et al. Dystrophin-like Complexes in Brain 651
blotting a range of subcellular fractions, including SMs and
PSDs prepared from rat forebrain (Fig. 5). Immunoblots
were incubated with a panel of antibodies specific for the
dystrobrevins, dystrophin and its isoforms, the syntro-
phins, and the PSD-enriched protein, PSD-95 (Fig. 5).
b-Dystrobrevin was found to be highly enriched in the
PSD fraction, when compared with the light membrane
(LM) and SM fractions (Fig. 5 A). The LM fraction com-
prises membrane fragments primarily of nonsynaptic ori-
gin. This result was confirmed using the b-dystrobrevin–
specific antibody, b521 (data not shown). By contrast,
a-dystrobrevin-1 was found in most fractions and was only
moderately enriched in the PSD fraction, when compared
with the LM and SM fractions (Fig. 5, A and B). In control
experiments, the enrichment of the PSD protein, PSD-95,
was determined in the same subcellular fractions. As ex-
pected, PSD-95 was highly enriched in the PSD fraction,
compared with the LM and SM fractions (Fig. 5 E; Cho et
al., 1992).
To determine whether the potential dystrobrevin-bind-
ing proteins were PSD-enriched, duplicate blots were in-
cubated with antidystrophin and antisyntrophin antibod-
ies. Dystrophin and Dp71 were enriched in the PSD
fraction (Fig. 5 C). Furthermore, Dp140, which is thought
to be located in perivascular astrocytes (Lidov et al., 1995),
was not PSD-enriched. The enrichment of Dp71 in the
PSD was confirmed with the MANDRA1 mAb that is
raised against the COOH terminus of dystrophin (Fig. 5
D). On longer exposures, dystrophin was detected in the
PSD preparations with MANDRA1 (data not shown).
Also, the syntrophins were found to be PSD-enriched
(Fig. 5 F). The SYN1351 mAb detects a doublet of pro-
teins of z59-kD that could correspond to the two syntro-
phin isoforms (a and b2) found in brain (Górecki et al.,
1997). Thus, several proteins that are potentially associ-
ated with b-dystrobrevin are PSD-enriched.
To examine the biochemical association of the dystro-
brevins with SMs in brain, synaptosomes were prepared
and solubilized with a panel of detergents and buffers. The
experiments were not carried out on PSDs due to the
highly insoluble nature of this material. The distribution of
the dystrobrevins in subcellular fractions was determined
by immunoblotting. Interestingly, the dystrobrevins were
found in most fractions, including the soluble fraction and
the nuclear pellet (Fig. 6, upper panel), whereas the major-
Figure 5. Subcellular fractionation of the dystrophin-related pro-
teins in the brain. The enrichment of b-dystrobrevin (A), a-dys-
trobrevin-1 (B), dystrophin isoforms (C and D), PSD-95 (E), and
syntrophin (F) in a range of subcellular fractions prepared from
rat forebrain, including SMs and postsynaptic densities, was de-
termined by Western blotting. The antibody bCT-FP detects
b-dystrobrevin and a-dystrobrevin-1 and -2 (A). b-Dystrobrevin
is highly enriched in the PSD fraction, whereas a-dystrobrevin-1
is not enriched (A and B). Although only a minor component in
brain extracts, a band corresponding to a-dystrobrevin-2 is also
enriched in the PSD (A). Dystrophin and Dp71, detected with
the antibody 2166, are also detected in PSDs (C). While Dp71 is
found in a wide range of fractions, the majority of dystrophin is
found in the PSD fraction. The enrichment of Dp71 in the PSD
fraction was confirmed with the MANDRA1 mAb (D). E, Shows
the enrichment of PSD-95 in the PSD fraction. Similarly, syntro-
phin detected with the pansyntrophin mAb, SYN1351, is also
PSD-enriched (F). The positions of the molecular weight stan-
dards are indicated.
Figure 6. Distribution of the dystrobrevins and dystrophin in
subcellular fractions. Upper panel, Western blot of brain extracts
incubated with bCT-FP, showing the distribution of b-dystrobre-
vin and a-dystrobrevin-1 and -2 in the protein fractions. Lower
panel, Western blot of brain extracts incubated with the antibody
2166, showing the distribution of dystrophin and Dp71 in the
fractions. Lane 1, total homogenate; lane 2, nuclear pellet; lane 3,
postnuclear supernatant; lane 4, soluble; lane 5, wash 1; lane 6,
wash 2; and lane 7, crude synaptosomes. The positions of the mo-
lecular weight standards are indicated.The Journal of Cell Biology, Volume 147, 1999 652
ity of dystrophin and Dp71 was found in the crude mem-
brane and synaptosomal fractions (Fig. 6, lower panel).
Most proteins that are PSD-enriched are only solubilized
using high concentrations of ionic detergents (Kennedy,
1997). To determine the extractability of the dystrobrevins
from crude synaptosomes, washed crude synaptosomes
were resuspended in a variety of buffers or in PBS con-
taining different detergents (Table I). a- and b-dystrobre-
vin, dystrophin, and Dp71 were completely solubilized in
2% SDS and 2% N-lauroylsarcosine. However, a-dystro-
brevin-1 was partially solubilized in 2% deoxycholic acid
also, whereas b-dystrobrevin, dystrophin, and Dp71 were
insoluble in this detergent. These data suggest that b-dys-
trobrevin and dystrophin are tightly associated with cy-
toskeletal structures, predominantly the PSD. In control
experiments, the extractability of PSD-95 was also deter-
mined. PSD-95 was only extracted in 2% SDS (Table I).
Dystrobrevin Interactions with Dystrophin, Dp71,
and Utrophin
To examine the interactions between b-dystrobrevin and
the dystrophin family of proteins in brain, reciprocal im-
munoprecipitations were performed on rat brain and liver
Table I. Solubilization of Proteins from Crude Synaptosomes
Extraction buffer b-Dystrobrevin a-Dystrobrevin-1 Dystrophin Dp71 PSD-95
PBS 22 2 2 2
0.1 M NaHCO3, pH 11.5 22 2 2 2
1 M Tris, pH 8.0 22 2 2 2
2% SDS 11 11 11 11 11
2% deoxycholate 21 2 2 2
2% Tween-20 22 2 2 2
2% Triton X-100 22 2 2 2
2% N-lauroylsarcosine 11 11 11 11 1/2
2% digitonin 22 2 2 2
Soluble and insoluble proteins extracted from crude synaptosomes were analyzed by Western blotting. The amount of protein extracted from the synaptosomes was scored arbi-
trarily as follows: 11, fully soluble; 1, partially soluble; 1/2, weakly soluble; and 2, insoluble.
Figure 7. Association of b-dystro-
brevin with dystrophin in the brain.
RIPA extracts of rat brain (A) and
rat liver (B) were immunoprecipi-
tated with b521 (lane 1), 2166 (lane
2), 2401 (lane 3), and URD40 (lane
4). The coimmunoprecipitated pro-
teins were detected with the anti-
body listed below each panel. In
brain,  b-dystrobrevin is only immu-
noprecipitated by 2166 and the cog-
nate antibody (A, upper panel).
Reciprocal immunoprecipitation by
b521 detected with antibody 2166
reveals that dystrophin, and not
Dp71 and Dp140, is the only pro-
tein that coimmunoprecipitates
with  b-dystrobrevin (A, middle
panel).  b-dystrobrevin is not immu-
noprecipitated by 2401 or URD40
(A, lower panel). In control experi-
ments on rat liver that demonstrate
the efficacy of each antibody for
immunoprecipitation, b-dystrobre-
vin is immunoprecipitated by 2166,
2401, and URD40 (B, upper panel).
Reciprocal immunoprecipitations
confirm the association of b-dystro-
brevin with Dp71 (B, middle panel)
and Dp71DC (B, lower panel) in rat
liver. The loading control (c) in
each experiment, RIPA brain ex-
tract (A) or RIPA liver extract (B),
is equivalent to 10% of the input
protein from each immunoprecipitation. The 100-kD protein in lane 1 (* in the upper and middle panels) is an IgG cross-reactive pro-
tein and is detected with the secondary antibody alone. The rabbit IgG heavy chain and the positions of the molecular weight standards
are indicated.Blake et al. Dystrophin-like Complexes in Brain 653
using a panel of polyclonal antibodies. For these experi-
ments, rat tissue was used because rat b-dystrobrevin has a
slightly higher relative mobility on SDS-PAGE, compared
with mouse b-dystrobrevin. This enables a better separa-
tion of b-dystrobrevin from the rabbit IgG heavy chain.
Rat liver was used as a control tissue because it is an abun-
dant source of b-dystrobrevin and can therefore be used to
check the efficacy of the antibodies used for immunopre-
cipitation. In brain, b-dystrobrevin was only coimmuno-
precipitated with the antidystrophin antibody 2166 (Fig. 7
A, upper panel). In reciprocal experiments, b521 coimmu-
noprecipitated dystrophin (Fig. 7 A, middle panel). On
long exposures, Dp71 was also detected, albeit weakly,
in b-dystrobrevin immunoprecipitates (Fig. 7 A, middle
panel). Although Dp140 was immunoprecipitated by 2166,
no Dp140 was coimmunoprecipitated with b-dystrobrevin.
Furthermore, 2401 and URD40 failed to coprecipitate b-dys-
trobrevin (Fig. 7 A, lower panel). In the liver, b-dystrobre-
vin coimmunoprecipitated with Dp71, Dp71DC, and utro-
phin (Fig. 7 B). These data show that b-dystrobrevin is
specifically associated with dystrophin in the brain, but can
also bind to Dp71 or utrophin in the liver.
To determine the composition of a-dystrobrevin-1–con-
taining protein complexes in the brain, a-dystrobrevin-1
was immunoprecipitated from rat brain with a panel of
polyclonal antibodies (Fig. 8). a-Dystrobrevin-1 was coim-
munoprecipitated by 2166 and URD40 (Fig. 8, upper
panel). However, the relative amounts of a-dystrobrevin-1
immunoprecipitated by each antibody were very different,
suggesting that the major complex formed is between
a-dystrobrevin-1 and Dp71. Reciprocal immunoprecipita-
tions confirmed the association of a-dystrobrevin-1 with
Dp71 (Fig. 8, middle panel) and utrophin (Fig. 8, upper
panel). No a-dystrobrevin-1 was immunoprecipitated by
b521, showing that b-dystrobrevin and a-dystrobrevin-1
are in different protein complexes. Furthermore, Dp140
and dystrophin failed to immunoprecipitate with a-dystro-
brevin-1 or utrophin (data not shown).
Dystrobrevin Interactions in Dystrophin-deficient Mice
The syntrophin family of proteins have been shown to
bind directly to a-dystrobrevin in muscle (Ahn and
Kunkel, 1995). To investigate this interaction in brain, we
examined the association of the dystrobrevins with syntro-
phin in the presence and absence of dystrophin and Dp71.
The pansyntrophin antibody, SYN1351, was used to
immunoprecipitate syntrophin-containing protein com-
plexes from RIPA-extracted crude membranes prepared
from the brains of normal C57 mice, dystrophin–deficient
mdx mice, and mdx3Cv mice, which lack dystrophin and
all the COOH-terminal dystrophin isoforms (Cox et
al., 1993). The two predominant dystrobrevin isoforms
present in brain, a-dystrobrevin-1, and b-dystrobrevin are
precipitated with SYN1351 (Fig. 9 A, upper panel). Fur-
thermore, a protein corresponding to a-dystrobrevin-2
was also precipitated by SYN1351. The amount of protein
precipitated from each mouse strain appeared to be simi-
lar, indicating that the interaction between the dystrobre-
vins and syntrophin was unperturbed by the absence of
dystrophin and Dp71 (Fig. 9 A, middle panels). As ex-
pected, no dystrophin cross-reactive proteins were immu-
noprecipitated with SYN1351 from the brains of mdx3Cv
mice (Fig. 9 A, middle panel). To exclude the possibility
that nonspecific protein precipitation had occurred, dupli-
cate Western blots were incubated with an mAb raised
against the synaptic vesicle protein, Munc18. Munc18 was
not detected in immunoprecipitates from any of the mouse
strains, indicating that the SYN1351 antibody specifically
immunoprecipitated dystrobrevin and dystrophin-contain-
ing complexes (Fig. 9 A, lower panel). Furthermore, no
apparent difference in dystrobrevin immunoreactivity in
the brains of normal mice, compared with dystrophin-defi-
cient mice, was found (data not shown). In control experi-
ments, we investigated the association of syntrophin with
a-dystrobrevin in skeletal muscle extracts prepared from
normal and mdx mice. By contrast to the situation in
brain, the absence of dystrophin results in a dramatic
reduction in the amount of a-dystrobrevin-1 and -2 asso-
ciated with syntrophin (Fig. 9 B). These results are con-
sistent with the reduction of a-dystrobrevin immunoreac-
tivity at the sarcolemma of dystrophin-deficient muscle
(Nawrotzki et al., 1998). Thus, the lack of dystrophin in
muscle affects the association of a-dystrobrevin and syn-
trophin, whereas in the brain, this interaction is apparently
unaltered by the absence of dystrophin or Dp71.
Figure 8. Association of a-dystrobrevin-1 with Dp71 and utro-
phin in the brain. RIPA extracts of rat brain were immunoprecip-
itated with b521 (lane 1), URD40 (lane 2), 2166 (lane 3), a1CT-FP
(lane 4). Immunoprecipitated proteins were analyzed by Western
blotting with bCT-FP (upper panel), 2166 (middle panel), and
URD40 (lower panel). In brain extracts, a-dystrobrevin-1 coim-
munoprecipitates predominantly with Dp71, but also with utro-
phin. Reciprocal coimmunoprecipitations confirm these associa-
tions. The loading control (c) in each experiment was RIPA brain
extract, and is equivalent to 10% of the input protein from each
immunoprecipitation. The rabbit IgG heavy chain and the posi-
tions of the molecular weight standards are indicated.The Journal of Cell Biology, Volume 147, 1999 654
Discussion
In this paper, we have presented several lines of evidence
showing that b-dystrobrevin is a component of a DPC in
neurons. To the best of our knowledge, this is the first ex-
ample of a protein that is directly and specifically associ-
ated with dystrophin in the brain. We have shown that the
closest relative of b-dystrobrevin,  a-dystrobrevin-1, in
common with several other components of the DPC, is as-
sociated with perivascular astrocytes and other glial cells.
Thus, despite extensive sequence homology, both proteins
are differentially distributed in the brain, where they form
distinct protein complexes.
b-Dystrobrevin Localization in the Brain
In the brain, b-dystrobrevin is found in neurons in the cor-
tex, hippocampus, and cerebellum, where it is associated
with neuronal somata, dendrites, and nuclei (Fig. 2). This
location is similar to that described for dystrophin (Fig. 4;
Lidov et al., 1990, 1993). The location of b-dystrobrevin
and dystrophin in the same types of neurons supports our
proposal that these proteins form part of a neuronal DPC-
like complex. However, there are some distinct differences
between the neuronal locations of b-dystrobrevin and dys-
trophin. For example, in the cerebellum, b-dystrobrevin is
predominantly expressed in granule cells and in Purkinje
cell somata (Fig. 2 F). By contrast, dystrophin immunore-
activity was not found in granule cell neurons, but pre-
dominated in the Purkinje cell somata and dendrites and
in perivascular astrocytes (Fig. 4 B). Interestingly, b-dys-
trobrevin is found at sites that are not reported to express
dystroglycan, such as granule cells and axons (Blake, D.J.,
unpublished results; Tian et al., 1996). Since dystroglycan
is a bind partner for dystrophin and its isoforms, these data
could suggest that a proportion of b-dystrobrevin is not as-
sociated with DPC-like complexes in the brain.
The association of b-dystrobrevin with some neuronal
nuclei reflects this theme (Fig 2). This result is supported
by the presence of significant amounts of b-dystrobrevin
in the nuclear pellet, compared with the content of Dp71
and dystrophin in the same fraction (Fig. 6). b-dystrobre-
vin lacks an obvious nuclear localization signal, but does
have some sequence features typical of nuclear proteins,
such as the zinc finger-like ZZ domain (Ponting et al.,
1996). It is interesting to speculate that b-dystrobrevin
may translocate from the neuronal membrane to the nu-
cleus. This mechanism has been described for a number of
proteins that are involved in the acquisition of long-term
memory (Abel and Kandel, 1998; Deisseroth et al., 1998).
A similar mechanism has been demonstrated for b-cate-
nin, a protein that plays a dual role in cadherin-mediated
cell adhesion at specialized submembranous sites and in
Wnt-signaling in the nucleus. Like b-dystrobrevin, b-cate-
nin is found at the membrane, in the cytoplasm, and nu-
cleus, but has no obvious nuclear import signal (Fagotto
et al., 1998; Wodarz and Nusse, 1998).
While it is difficult to envisage a role for members of the
DPC in the nucleus, it should be emphasized that the re-
cently characterized syntrophin-binding protein, SAST
(syntrophin-associated serine/threonine kinase), is also
found in the nuclei of hippocampal pyramidal neurons
(Lumeng et al., 1999). Our data and the data of Lumeng
Figure 9. The dystrobrevin–syntrophin complex. A, Association
of syntrophin with the dystrobrevins in the brain RIPA extracts
prepared from C57, mdx, and mdx3Cv mouse brains were immu-
noprecipitated with the SYN1351 pansyntrophin mAb. The
coimmunoprecipitated proteins were Western blotted and incu-
bated with the following antibodies: bCT-FP (upper panel); 2166
(second panel); SYN1351 (third panel); and Munc18 (lower
panel). The RIPA-soluble brain extract that was used for im-
munoprecipitation was included as a control (c). Equivalent
amounts of the three dystrobrevin isoforms are coimmunoprecip-
itated with the SYN1351 antibody in extracts from the three
mouse strains (upper panel). Dp71 is coimmunoprecipitated by
SYN1351 in C57 and mdx extracts (second panel). The levels of
syntrophin precipitated from each extract are shown to be equiv-
alent (third panel). Munc18 is not present in SYN1351 immuno-
precipitates (lower panel). The rabbit IgG heavy chain and the
positions of the molecular weight standards are indicated. B, As-
sociation of syntrophin with a-dystrobrevin-1 and -2 in muscle.
RIPA extracts prepared from C57 and mdx mouse muscle were
immunoprecipitated with the SYN1351 antibody. The coimmu-
noprecipitated proteins were Western blotted and incubated with
bCT-FP.  a-Dystrobrevin-1 and -2 are precipitated with the
SYN1351 mAb. The amount of a-dystrobrevin-1 and -2 precipi-
tated from mdx muscle are significantly less than the levels pre-
cipitated from C57 muscle. The positions of the molecular weight
standards are indicated.Blake et al. Dystrophin-like Complexes in Brain 655
and colleagues raise the possibility that DPC-like com-
plexes may be present in the nucleus. Clearly, establishing
a role for these proteins in the nucleus warrants further in-
vestigation.
A Role for the Neuronal DPC-like Complex in
Brain Function?
We have shown that b-dystrobrevin colocalizes and coim-
munoprecipitates with dystrophin in neurons. Further-
more, b-dystrobrevin, dystrophin, and syntrophin are
PSD-enriched. These data strongly suggest that b-dystro-
brevin is a neuronally expressed dystrophin-associated
protein. Additionally, b-dystrobrevin coimmunoprecipi-
tates with syntrophin (Fig. 9) and interacts with the syntro-
phin family of proteins in the yeast two-hybrid system
(Benson, M.A., and D.J. Blake, unpublished results). Our
data suggest that the DPC-like complex in neurons is com-
posed of dystrophin, b-dystrobrevin, and syntrophin (Fig.
10 A). Therefore, by analogy to the situation in muscle,
this complex may be involved in the etiology of cognitive
impairment in DMD patients. The molecular identity of
other components of this complex is currently unknown.
However, a wealth of circumstantial evidence suggests
that nNOS may also be associated with the dystrophin–
b-dystrobrevin complex in neurons.
In the brain, a-syntrophin interacts with nNOS through
reciprocal PDZ domains (Brenman et al., 1995, 1996;
Hashida-Okumura et al., 1999; Hillier et al., 1999). Fur-
thermore, nNOS also binds to the PSD proteins, PSD-93
and PSD-95, which are involved in N-methyl D-aspartate
(NMDA) receptor clustering (Brenman et al., 1996). This
interaction places nNOS in proximity to the NMDA re-
ceptor at the postsynaptic membrane of excitatory syn-
apses (Kornau et al., 1995; Niethammer et al., 1996). Our
finding that b-dystrobrevin and the syntrophins are PSD-
enriched and present in a complex offers a separate mech-
anism to locate nNOS to the postsynaptic membrane.
Therefore, it is a distinct possibility that the DPC-like
complex at the neuronal membrane contains nNOS bound
to syntrophin, b-dystrobrevin, and dystrophin (Fig. 10 A).
This interaction, coupled with the role of nitric oxide in
the calcium-dependent processes of neurotoxicity, could
render dystrophin-deficient neurons more susceptible to
metabolic or physiological insults (Christopherson and
Bredt, 1997). This hypothesis is supported by the findings
that dystrophin-deficient neurons have enhanced suscepti-
bility to hypoxia-induced loss of synaptic transmission
(Mehler et al., 1992) and have increased intracellular cal-
cium (Hopf and Steinhardt, 1992). Hypoxia and hyperex-
citation cause parallel increases in intracellular calcium in
neurons that can ultimately lead to cell death. Consistent
with these ideas, an increase in neuronal cell loss has been
described in some patients with DMD (Jagadha and
Becker, 1988).
a-Dystrobrevin-1 Localization and Association in
the Brain
We have shown that a-dystrobrevin-1 is found in perivas-
cular astrocytes and in Bergmann glia of the cerebellum
(Fig. 3). The pattern of a-dystrobrevin-1 immunoreactivity
in the brain is reminiscent of utrophin that was shown to
be associated with the cerebral microvasculature and, in
particular, the foot processes of perivascular astrocytes
(Khurana et al., 1992). Other proteins known to be associ-
ated with the DPC, such as dystroglycan (Tian et al.,
1996), laminin-2 (Jucker et al., 1996), the dystrophin iso-
form Dp140 (Lidov et al., 1995), and agrin (Barber and
Lieth, 1997) are expressed in perivascular regions of the
brain. The accumulation of a-dystrobrevin-1 and the DPC
components at these sites may play a role in the pathogen-
esis of viral infections of the central nervous system since
a-dystroglycan has been shown to be a receptor for several
arenaviruses (Cao et al., 1998). Thus, DPC-like complexes
in perivascular astrocytes may form part of the permeabil-
ity barrier between the circulatory system and the brain.
In astrocytes, a-dystrobrevin-1 is predominantly associ-
ated with Dp71 and syntrophin. However, a minor com-
plex is also formed between a-dystrobrevin-1 and utro-
phin. Therefore, it is possible that different DPC-like
complexes are maintained within glial cells. It is notewor-
thy that Dp140, a protein that is expressed in glial cells as-
sociated with brain vasculature (Lidov et al., 1995), does
not copurify with a-dystrobrevin-1 in brain extracts (Fig.
8). Since a-dystrobrevin-1 is only found in glial cells, a
large proportion of Dp71 must also be expressed by glia,
accounting for the perivascular staining of the antidystro-
phin antibody 2166 in the brain (Fig. 5). Thus, the DPC-
like complex containing a-dystrobrevin-1 in glia is pre-
dominantly composed of a-dystrobrevin-1, Dp71, and
syntrophin (Fig. 10 B). There is also some evidence that
Figure 10. Dystrobrevin containing complexes in the brain. Hy-
pothetical model showing the organization of DPC-like com-
plexes in neurons (A) and glia (B). In neurons, b-dystrobrevin is
associated with dystrophin and syntrophin. In glia, such as
perivascular astrocytes, a-dystrobrevin-1 is found in a complex
with Dp71 and syntrophin. In both instances, we propose that
there is a transmembrane binding partner (filled oval) for dystro-
phin and Dp71, similar to the dystroglycan–dystrophin complex
in muscle. For clarity, the minor complexes containing b-dystro-
brevin and Dp71 and a-dystrobrevin-1 and utrophin are not
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Dp71 may be present in neurons, especially in the dentate
gyrus (Górecki et al., 1998). It is possible that neuronally
derived Dp71 is associated with b-dystrobrevin because a
small amount of Dp71 was detected amongst the proteins
immunoprecipitated by b521 (Fig. 8). Furthermore, we
have shown that Dp71 is PSD-enriched (Fig. 5, C and D).
However, some glial-derived proteins, such as a-dystrobre-
vin-1, are clearly present in PSD preparations. PSDs are
known to absorb proteins of a nonneuronal origin, such as
glial fibrillary acidic protein, during their isolation (Matus et
al., 1980), which could account for the presence of a-dys-
trobrevin-1 and Dp71 in the PSD fractions.
Dystrobrevin Interactions in Mutant Mice
Central to the pathogenesis of muscular dystrophy is the
disruption of the DPC in muscle. In dystrophin-deficient
muscle, there is a dramatic reduction in the levels of DPC
at the sarcolemma, possibly due to a failure of this com-
plex to assemble (Holt and Campbell, 1998). However, to
the best of our knowledge, no one has examined the as-
sembly of DPC-like complexes in other tissues. In this pa-
per, we have shown that the dystrobrevin-syntrophin com-
plex in the brain is apparently unaffected by the absence
of dystrophin and Dp71 (Fig. 9 A). Furthermore, dystro-
brevin-immunoreactivity appears normal in the brains of
dystrophin-deficient mice (Blake, D.J., unpublished re-
sults). By contrast, in muscle this complex is destabilized
in the absence of dystrophin (Fig. 9 B). This difference be-
tween the assembly or stability of DPC-like complexes in
muscle and brain may explain why the absence of dystro-
phin or Dp71 in the brain produces a relatively mild phe-
notype, compared with the devastating muscle pathology
seen in patients with DMD and the mdx mouse. The anal-
ysis of several mouse mutants has elegantly demonstrated
that the absence of individual components of the DPC
complex in muscle often results in muscular dystrophy
(Duclos et al., 1998; Hack et al., 1998; Grady et al., 1999).
Therefore, it can be argued that the each component of
the DPC contributes directly to the pathogenesis of mus-
cular dystrophy. However, our data raises the possibility
that the assembly of DPC-like complexes in neurons and
glia is largely unaffected by the absence of dystrophin and
its isoforms. While these findings seem to preclude a con-
tributory role for b-dystrobrevin in the cognitive dysfunc-
tion that affects some DMD patients, it should be empha-
sized that, due to the refractory nature of the PSD, subtle
differences in the assembly of the dystrophin–dystrobrevin
complex at postsynaptic sites may go undetected.
In conclusion, we have shown that there are fundamen-
tal differences in the composition of DPC-like complexes
in neurons and glia, and between the assembly and stabil-
ity of the DPC in muscle and brain. The identification of
b-dystrobrevin as a binding partner for dystrophin and
their enrichment in PSDs suggests that both proteins are
components of central synapses and thereby define the
neuronal DPC. This discovery is particularly relevant be-
cause a large proportion of DMD patients have mild cog-
nitive impairment. The identification of b-dystrobrevin in
multiple subcellular compartments in the brain could in-
voke another route for the propagation of extra- or intra-
cellular signals to different regions of the neuron. It is
tempting to speculate that some of the cognitive difficul-
ties experienced by DMD patients may be caused by alter-
ations in the b-dystrobrevin–dystrophin complex at PSDs.
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